Japanese ethnicity compared with caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: A collaborative epidemiologic study of the national hospital organization study group for lung cancer (NHSGLC) in japan and a southern california regional cancer registry databases

Journal of Thoracic Oncology

Volumn 5, Issue 7, 2010, Pages 1001-1010

  Kawaguchi, Tomoya ^a   Matsumura, Akihide ^a   Fukai, Shimao ^b   Tamura, Atsuhisa ^c   Saito, Ryusei ^d   Zell, Jason A ^e   Maruyama, Yosihito ^f   Ziogas, Argyrios ^e   Kawahara, Masaaki ^a   Ignatius Ou, Sai Hong ^e  

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b The Center of Chest Diseases and Severe Motor Intellectual Disabilities   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d Shibukawa Medical Center   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Osaka Prefecture University   (Japan)

Author keywords

Cancer registry; Caucasian ethnicity; Japanese ethnicity; Never smoker; Non small cell lung cancer; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; ADENOCARCINOMA; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CANCER STAGING; CHILD; CLINICAL TRIAL; EPIDEMIOLOGY; ETHNOLOGY; INFANT; JAPAN; LARGE CELL CARCINOMA; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEWBORN; NON SMALL CELL LUNG CANCER; PATHOLOGY; PRESCHOOL CHILD; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; RETROSPECTIVE STUDIES; SMOKING; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954423520     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e2f607     Document Type: Article

References (22)

1. Parkin DM, Bray FJ, Ferlay L, et al. Global cancer statistics. CA Cancer J Clin 2002;55:74-108.
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers\a different disease. Nature 2007;7:778-790. (Pubitemid 47463669)
3. Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncology 2008;9:678-682. (Pubitemid 351878053)
4. Pirker B, Poreira JR, Szczesna A, et al. Centuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-1531.
5. Mok TS, Leong S, Liu X, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
6. Sculier J-P, Chansky K, Crowley J, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008;3:457-466. (Pubitemid 351630271)
7. Chansky K, Sculier J-P, Crowley J, et al. The IASLC lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4:792-801.
8. Ou S-HI, Ziogas A, Zell JA. Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 2009;4:1083-1093.
9. Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer\a multicenter study. Lung Cancer 2005;49:63-70. (Pubitemid 40798094)
10. Kawaguchi T, Matsurama A, Iuchi K, et al. Second primary cancers in patients with stage III non-small cell lung cancer successfully treated with chemo-radiotherapy. Jpn J Clin Oncol 2006;36:7-11. (Pubitemid 43210729)
11. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008;26:5589-5595.
12. Zell JA, Ou S-HI, Ziogas A, et al. Epidemiology of bronchioloalveolar carcinoma: improvement in survival after release of the 1999 WHO classification of lung tumors. J Clin Oncol 2005;23:8396-8405. (Pubitemid 46260235)
13. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-855. (Pubitemid 47181391)
14. Florescu M, Hasan B, Seymour L, et al. A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canda Clincal Trials Group study BR. 21. J Thorac Oncol 2008;3:590-598. (Pubitemid 351787301)
15. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
16. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-3546.
17. Sekine I, Nokihara H, Yamamoto N, et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 2006;53:157-164. (Pubitemid 43994238)
18. Kenfield SA, Wei EK, Stampfer MJ, et al. Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control 2008;17:198-204.
19. Khuder SA, Mutgi AB. Effect of smoking cessation on major histologic types of lung cancer. Chest 2001;120:1577-1583. (Pubitemid 33078475)
20. Nordquist LT, Simon GR, Cantor A, et al. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 2004;126:347-351. (Pubitemid 39093415)
21. Kubota K, Kawahara M, Ogawara M, et al. Vinorelbine plus gemcitab-ine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008;9:1135-1142.
22. Kim HS, Park K, Jun HJ, et al. Comparison of survival in advanced non-small cell lung cancer patients in the pre-and post-gefitinib eras. Oncology 2009;76:239-246.